Phathom Pharmaceuticals, Inc.(PHAT)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Phathom Pharmaceuticals, Inc. (PHAT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PHAT at 40.9/100 on a 32-signal composite quality model, placing it at rank #2,083 of 2,961 stocks — the bottom half of the AI-ranked universe. PHAT scores in the top quartile across revenue growth (99.3). Areas of concern include balance sheet strength (6.5) and profitability (12.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Phathom Pharmaceuticals, Inc. reports quarterly revenue of $74.3M, net income of $-17.6M, free cash flow of $-2.0M. Top institutional holders of PHAT by reported 13-F value include Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, BlackRock, based on the most recent SEC filings. PHAT trades on the Nasdaq exchange and files with the SEC under CIK 1783183. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PHAT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Phathom Pharmaceuticals, Inc. directly from SEC EDGAR.